Charles River Laboratories (NYSE:CRL) — Market Cap & Net Worth
Market Cap & Net Worth: Charles River Laboratories (CRL)
Charles River Laboratories (NYSE:CRL) has a market capitalization of $8.90 Billion ($8.90 Billion) as of June 17, 2026. Listed on the NYSE stock exchange, this USA-based company holds position #2458 globally and #888 in its home market, demonstrating a -0.89% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Charles River Laboratories's stock price $184.79 by its total outstanding shares 48167730 (48.17 Million). Review Charles River Laboratories (CRL) financial obligations to assess the company's total debt and financial obligations.
Charles River Laboratories Market Cap History: 2015 to 2026
Charles River Laboratories's market capitalization history from 2015 to 2026. Data shows growth from $3.87 Billion to $8.90 Billion (9.94% CAGR).
Index Memberships
Charles River Laboratories is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Dow Jones Biotechnology
DJUSBT
|
$1.08 Trillion | 0.82% | #14 of 39 |
|
S&P 500 Index
GSPC
|
$62.23 Trillion | 0.01% | #472 of 503 |
Weight: Charles River Laboratories's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Charles River Laboratories Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Charles River Laboratories's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
2.39x
Charles River Laboratories's market cap is 2.39 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $3.67 Billion | $1.68 Billion | $154.76 Million | 2.18x | 23.71x |
| 2017 | $5.27 Billion | $1.86 Billion | $123.36 Million | 2.84x | 42.74x |
| 2018 | $5.45 Billion | $2.27 Billion | $226.37 Million | 2.41x | 24.08x |
| 2019 | $7.36 Billion | $2.62 Billion | $252.02 Million | 2.81x | 29.20x |
| 2020 | $12.04 Billion | $2.92 Billion | $364.30 Million | 4.12x | 33.04x |
| 2021 | $18.15 Billion | $3.54 Billion | $390.98 Million | 5.13x | 46.42x |
| 2022 | $10.50 Billion | $3.98 Billion | $486.23 Million | 2.64x | 21.59x |
| 2023 | $11.39 Billion | $4.13 Billion | $474.62 Million | 2.76x | 23.99x |
| 2024 | $8.89 Billion | $4.05 Billion | $10.30 Million | 2.20x | 863.53x |
| 2025 | $9.61 Billion | $4.02 Billion | -$144.34 Million | 2.39x | N/A |
Competitor Companies of CRL by Market Capitalization
Companies near Charles River Laboratories in the global market cap rankings as of June 17, 2026.
Key companies related to Charles River Laboratories by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #127 globally with a market cap of $177.57 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #182 globally with a market cap of $128.10 Billion USD.
- IDEXX Laboratories Inc (NASDAQ:IDXX): Ranked #626 globally with a market cap of $44.18 Billion USD.
- LONZA GROUP UNSP.ADR 1/10 (F:LO3A): Ranked #663 globally with a market cap of $41.04 Billion USD ( €35.10 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #127 | Thermo Fisher Scientific Inc | NYSE:TMO | $177.57 Billion | $472.63 |
| #182 | Danaher Corporation | NYSE:DHR | $128.10 Billion | $181.35 |
| #626 | IDEXX Laboratories Inc | NASDAQ:IDXX | $44.18 Billion | $573.00 |
| #663 | LONZA GROUP UNSP.ADR 1/10 | F:LO3A | $41.04 Billion | €54.50 |
Charles River Laboratories Historical Marketcap From 2015 to 2026
Between 2015 and today, Charles River Laboratories's market cap moved from $3.87 Billion to $ 8.90 Billion, with a yearly change of 9.94%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $8.90 Billion | -7.36% |
| 2025 | $9.61 Billion | +8.06% |
| 2024 | $8.89 Billion | -21.91% |
| 2023 | $11.39 Billion | +8.49% |
| 2022 | $10.50 Billion | -42.17% |
| 2021 | $18.15 Billion | +50.80% |
| 2020 | $12.04 Billion | +63.56% |
| 2019 | $7.36 Billion | +34.97% |
| 2018 | $5.45 Billion | +3.41% |
| 2017 | $5.27 Billion | +43.65% |
| 2016 | $3.67 Billion | -5.22% |
| 2015 | $3.87 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 17th, 2026 the market cap of Charles River Laboratories was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $8.90 Billion USD |
| MoneyControl | $8.90 Billion USD |
| MarketWatch | $8.90 Billion USD |
| marketcap.company | $8.90 Billion USD |
| Reuters | $8.90 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Charles River Laboratories
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in … Read more